🔴 Lipocine is trading 5% down; no clear company-specific catalyst

Lipocine is trading at $2.08, down 5.45%, with no clear Lipocine-specific negative catalyst identified for October 1.

• A director’s reported September 28 purchase of 12,561 shares was disclosed, but it does not explain the decline.
• Broader markets faced pressure from surging Treasury yields. Reuters reported the 10-year yield hit 5.306%, its highest level since mid-June 2007; this is a possible macro backdrop, but evidence does not establish it as the direct cause of Lipocine’s move.